FayeMiriamFellerMD

Hematologic Oncology

Physician

Dr. Feller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2007 - 2010
Icahn School of Medicine at Mount SinaiClass of 2007

PubMed

17 citations
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
John Mascarenhas, Claire N Harrison, Jean-Jacques Kiladjian, Rami S Komrokji, Steffen Koschmieder
Future Oncology. 2022-07-01
48 citations
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis
John Mascarenhas, Rami S. Komrokji, Francesca Palandri, Bruno Martino, Dietger Niederwieser
Journal of Clinical Oncology. 2021-06-17
41 citations
Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation
Camelia Iancu-Rubin, David Gajzer, Goar Mosoyan, Faye M. Feller, John Mascarenhas
Experimental Hematology. 2012-07-01

Abstracts/Posters

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapse...
Faye Feller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Geron Announces New Data to Be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (Imetelstat) in Myeloid Hematologic MalignanciesNovember 5th, 2024
Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (Imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDSJuly 26th, 2024
GERN Earnings Call for the Period Ending March 31, 2023May 11th, 2023
Join now to see all